Skip to content
Home/Companies/Biotech/Dark Blue Therapeutics
DB

Dark Blue Therapeutics

Biotech·UK·Exited 2026·Held 6yr

Dark Blue Therapeutics is a biotech company, headquartered in UK.

Entry
2020
Hold
6yr
Exit
2026
Est. EV
–

Who owns Dark Blue Therapeutics?

Dark Blue Therapeutics was owned by Oxford Science Enterprises through Oxford Science Enterprises Balance Sheet (2015 vintage) from 2020 to 2026, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-06-11

Oxford Science Enterprises
Investor
Oxford Science Enterprises
Oxford Science Enterprises Balance Sheet · 2015 · Balance Sheet

Key facts

HQUK
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2026

More from Oxford Science Enterprises Balance Sheet

Other portfolio companies in the same fund.

MiroBio
Exited 2022
BiotechUK· 2019
to
Oxford Ionics
Exited 2025
Deep TechUK· 2019
to
PepGen
Active
BiotechUnited States· 2018
Latent Logic
Exited 2019
AI/MLUK· 2017
to
Oxford Semantic Technologies
Exited 2024
AI/MLUK· 2017
to
Brill Power
Exited 2025
EnergyUK· 2016
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings